Approximately 6% of dog platelets are positive for staining with thiazole orange, a dye frequently used to stain ribonucleic acid. In this report, thiazole-orange positivity is shown to mark platelets that are less than 24 hours old. Dog platelets were derivatized in vivo with N-hydroxysuccinirnido biotin such that greater than 9596 of all platelets were biotinylated. Newly synthesized, nonbiotinylated platelets VALUATION of platelet production is required to differentiate between alternative etiologies of thrombocytopenia, ie, impaired production or increased utilization of platelets.' However, quantitative measurements of platelet production are not routinely available, although production can be inferred by evaluation of megakaryocytes in bone marrow aspirates or sections.' Ideally, a simple peripheral blood assay for estimating platelet production, analogous to red blood cell reticulocyte counts, would solve this problem.
VALUATION of platelet production is required to differentiate between alternative etiologies of thrombocytopenia, ie, impaired production or increased utilization of platelets.' However, quantitative measurements of platelet production are not routinely available, although production can be inferred by evaluation of megakaryocytes in bone marrow aspirates or sections.' Ideally, a simple peripheral blood assay for estimating platelet production, analogous to red blood cell reticulocyte counts, would solve this problem.
In 1969, Ingram and Coopersmith' showed RNA-like material in dog platelets after acute blood loss. These studies used a methylene blue staining procedure similar to that for red blood cell reticulocytes, and the methylene blue-positive cells were referred to as reticulated platelets. Subsequently Kienast and Schmitzj determined that platelets could be stained with thiazole orange and analyzed by flow cytometry similar to procedures used to detect RNA in reticulocytes. Studies with patient samples that were expected to have elevated levels of platelet synthesis did, in fact, show increased percentages of thiazole-orange-positive platelets. Auk et a1 and Rinder et a14-' have extended these studies to numerous clinical settings and have corroborated the earlier findings that platelet production appears to correlate with the percentage of thiazole-orange-positive platelets.
With the technique described, = 1% of normal human platelets are positive for thiazole orange, and staining is sensitive to ribonuclease digestion.' Although the correlations between thiazole-orange positivity and platelet production are suggestive that thiazole orange stains newly produced platelets, definitive proof has not been available. Additionally, no information is available which documents a time-dependent loss of thiazole-orange positivity from newly synthesized platelets. In this report we use in vivo biotinylation of dog platelets to show that newly synthesized platelets are thiazole-orange positive. Specifically, greater than 95% of existing platelets are biotinylated by infusion of N-hydroxysuccinimido-biotin (NHS-biotin). At subsequent times, the appearance of new, nonbiotinylated platelets allows evaluation of thiazole-orange binding by these newest platelets. The data show that newly synthesized platelets are thiazole-orange positive and that platelets remain thiazole-orange positive for less than 24 hours. Buflers. We used the following buffers: buffered saline-glucosecitrate (BSGC), pH 7.3; 129 mmol/L NaCl; 13.6 mmol/L Na, citrate: 1 1.1 mmol/L glucose; 1.6 mmol/L KHZPOI; 8.6 mmolfL NaH2POI, pH 7.3; acid citrate dextrose (ACD); 38.1 mmol/L citric acid; 74.8 mmol/L Na, citrate; 136 mmol/L glucose; phosphate buffered saline (PBS); 150 mmol/L NaCI; and 10 mmol/L NaHZPO,, pH 7.4.
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MATERIALS AND METHODS
Muteriuls
In vivo biotinylutions. Adult beagle dogs were obtained from Marshall Laboratories (North Rose, NY) and housed according t o regulations of the Institutional Animal Use and Care Committee of the University of Oklahoma Health Sciences Center (accredited by the American Association for Accreditation of Laboratory Animal Care). Dogs were biotinylated in vivo as described previously.'x Briefly, NHS-biotin (3.8 mgkg body weight) was dissolved in DMSO at 20 mg/mL with mild warming at 37°C. One half of the NHS-biotin was diluted into 20 mL of 0.9% saline and immediately infused into a front leg vein of the dog. Infusions were performed with a 21-g butterfly infusion set and a syringe pump at a Row rate of = 3 mL/min. Thirty minutes after the tirst infusion, the second half of the NHS-biotin was diluted into saline and infused as before. This staggered infusion of NHS-biotin' results in greater than 95% of all platelets being labeled with biotin (compare A and B in Fig  I ) .
A previous report used a single infusion of NHS-biotin with a resulting 80% of platelets biotinylated.' The proposed explanation for the incomplete biotinylation was that platelets pooled in the spleen were not exposed to NHS-biotin because of the very short in vivo life span of NHS-biotin" and the sluggish circulation of the spleen. Subsequently, we have adopted the double infusion technique described here with a 30-minute time period between biotinylations with the expectation that platelets present in the spleen during the first biotinylation would reequilibrate to the general circulation before the second labeling. Table 1 ).
ened by biotinylation of a splenectomized dog where a single infusion of NHS-biotin resulted in greater than 95% biotinylation (unpublished observation).
Streptuvidin-TRI-COLOR labeling. Blood samples were drawn into EDTA tubes and mixed continuously at room temperature. Analysis was initiated within 60 minutes of drawing the blood. Ten microliters of whole blood was diluted into 4 mL of BSGC, pH 7.3, and 400 pL of 3.7% formalin in BSGC, pH 7.3, was added. (All solutions used in this analysis were filtered through 0.45-pm filters.)
After 60 minutes of fixation, the sample was centrifuged at 1,5008 for IO minutes, and the pellet was resuspended in l mL BSGC, pH 7.3. These fixed samples can be stored at 4°C for at least 24 hours before analysis. Two hundred microliters of the fixed, washed blood sample was incubated with 4 pg/mL of streptavidin TRI-COLOR for 30 minutes at room temperature. TRI-COLOR is a Cy-5-derivatized phycoerythrin that is activated at 488 nm and has an emission peak at 667 nm. The 667-nm emission is observed in the FL, channel of 
CA) and has no cross-over into the FL, channel where thiazole orange is quantitated.
Thiazole-orange labeling. One hundred microliters of the streptavidin TRI-COLOR-labeled mixture was diluted into 1 mL of thiazole-orange reagent (Retic-COUNT) and reacted at room temperature for 1 hour. This sample was then used directly for flow cytometry.
Flow cytometry. Analysis was performed on a FACScan instmment equipped with a 488-nm argon laser and three-color detection.
The log settings used were FSC EOO; SSC 320; F L , 700 volts; FL, 500 volts; threshold 200 volts. No compensation was used. There is some cross-over of thiazole orange into the F L 3 channel, but this was not corrected. Initial gates were set with the forward-scatter/ side-scatter pattern characteristic of platelets, and 20,000 platelet events were acquired.
Ribonuclease treatments. Whole blood was fixed in formalin and washed as detailed above. Platelets were then permeabilized by incubation with 0.2% (wt/vol) saponin (final concentration from a filtered stock of 10% [wt/vol] in PBS) for 30 minutes at room temperature. Five micrograms/milliliter of ribonuclease were subsequently added and the incubation continued for 15 minutes at 37°C. Staining for streptavidin TRI-COLOR and thiazole orange were then performed as outlined above.
RESULTS
In vivo biotinylation results in covalent labeling of greater than 95% of platelets in dogs.' The biotin label is stable in and allows determination of platelet life As a result of these characteristics, biotinylation can also be used to tag existing cells and thereby identify newly synthesized cells by their lack of surface-bound biotin (see Discussion).
DALE ET AL Figure 1A shows the streptavidin TRI-COLOR and thiazole-orange labeling of a prebiotinylation sample. With this particular dog, 5.27% of all platelets are thiazole-orange positive (gate Rl), and this positivity is lost after incubation of fixed, permeabilized platelets with nbonuclease (see below). Ten minutes after in vivo biotinylation, greater than 95% of all platelets are biotin positive as indicated by the binding of streptavidin TRI-COLOR (Fig 1B) . The thiazoleorange-positive cells are also biotinylated and are now present in gate R2; furthermore, the total level of thiazole-orange-positive events did not change significantly as a result of biotinylation (5.55% thiazole-orange-positive events at 10 minutes postderivatization).
After biotinylation, samples were analyzed for the number of platelets that were thiazole-orange positive and biotin negative (gate R1); biotin-negative platelets are newly synthesized (see Discussion). The number of new platelets that are thiazole-orange positive and biotin negative increased with time (for example, compare Fig 1, C and H) . The progressive nature of the change in biotin-negative, thiazoleorange-positive platelets is illustrated in Fig 2, which summarizes data from three dogs. At 30 minutes, the number of biotin-negative, thiazole-orange-positive cells dropped from the prederivatization level of 5.21% i 0.07% (mean ? I SD; n = 3) to 0.72% ? 0.20% of the total population. Over the next 24 hours, the number of platelets in this RI gate gradually increased to 5.44% 2 0.53%.
An analysis of biotin-positive and thiazole-orange-positive platelets (gate R2) produces a similar but reciprocal plot (data not shown). These cells represent those already thiazole-orange-positive at the time of biotinylation, which are subsequently lost from gate R2, presumably into the large population of biotin-positive, thiazole-orange-negative platelets. Table 1 documents the effect of ribonuclease treatment on the thiazole-orange positivity of dog platelets. For these experiments, platelets were fixed with formalin as detailed above and permeabilized with 0.2% saponin. These data show that saponin exposure does not affect thiazole-orange staining; however, incubation of permeabilized platelets with ribonuclease does eliminate the thiazole-orange staining. Ribonuclease treatment of nonpermeabilized cells does not impact thiazole-orange staining (data not shown).
DISCUSSION
The data presented in this report document that thiazoleorange-positive platelets are newly synthesized platelets and that they remain thiazole-orange positive for less than 24 hours. The flow cytometric dot plots shown in Fig 1 clearly show the shift in the observed thiazole-orange-positive events from the biotin-positive gate (R2) to the biotin-negative gate (Rl) with time after biotinylation. An approximation of the kinetics for the appearance of thiazole-orange positivity in the biotin-negative gate is shown in Fig 2. The overall conclusion is quite clear that thiazole-orange-positive platelets are the youngest cells.
The slope of the graph in Fig 2 should reflect the life span of thiazole-orange positivity; however, minor alterations in the gate set between biotinylated and nonbiotinylated platelets in Fig 1 dramatically affect the recovery slope in Fig 2. Modest adjustments in the gate will shift the apparent life span from the 24 hours shown in Fig 2 to values as low as 12 hours. As a result, the precise period of time a platelet remains thiazole-orange positive cannot be determined from these experiments.
Platelet biotinylation in vivo allows existing platelets to be tagged and thereby discriminated from newly synthesized, nonbiotinylated platelets. However, a careful analysis of the "nonbiotinylated" population of platelets in this study as well as a previous report' will indicate that after in vivo biotinylation, newly appearing platelets are not totally lacking in surface biotin as indicated by a modest binding of PE-streptavidin (compare F L 3 levels of platelets in gate R1 in Fig 1, A and H) . There are two possible explanations for this phenomenon. Either megakaryocytes are biotinylated and subsequently produce biotinylated platelets or newly synthesized platelets adsorb small quantities of plasma proteins, which, in this case, happen to be biotinylated because the in vivo biotinylation reaction is nonselective. We have directly examined megakaryocytes 2 hours after in vivo biotinylation' and found very modest levels of biotinylation. Considering that megakaryocytes will fragment into many platelets, the biotin level per platelet will be insignificant, but may explain the modest levels seen here. The second explanation would require newly synthesized platelets to adsorb biotinylated plasma proteins (eg, fibrinogen or IgG) on their cell surface. There is no experimental support for this proposal, but it cannot be dismissed at this time. Whatever the explanation, the modest level of biotinylation exhibited by newly synthesized platelets does not interfere with their differentiation from fully biotinylated platelets.
These observations indicate that thiazole-orange analysis is potentially a reliable method to estimate platelet production. In addition, the percentage of thiazole-orange-positive platelets may serve as an estimate of mean platelet age under steady-state conditions. However, before thiazole-orange staining of platelets can be a useful tool clinically, several assay parameters need to be finalized. For example, whereas in this report and that of Kienast and Schmitz,3 whole blood was analyzed, others have used platelet-rich p l a~m a .~-~. " However, the primary problem with the use of thiazole orange is one of defining a threshold gate for positivity. Ault et a14 have set a gate that identifies 1% of platelets in a normal control as thiazole-orange positive. A simpler methodology for setting an analysis gate would enhance the assay, and recently Bonan et all0 have proposed use of thiazoleorange-stained reticulocytes as an internal marker for setting the fluorescence threshold for thiazole-orange-stained platelets. We and others4 have shown that ribonuclease treatment of permeabilized platelets eliminates thiazole-orange staining, but this approach may not be amenable to a routine assay.
Validation of thiazole orange as a marker of the very youngest platelets will also allow studies of anomalies associated with thrombocytopenias where bleeding may or may not occur despite low platelet counts." Because it is widely assumed and infrequently shown that young platelets are the most hemostatically active, a measure of mean platelet age, as determined by the percentage of very young platelets, may be useful in evaluation and management of thrombocytopenic patients.
